…
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
| Net income | -77.91M | -80.56M | -60.39M | -29.68M | -16.24M |
| Selling general administrative | 24.12M | 25.21M | 21.08M | 8.71M | 2.47M |
| Selling and marketing expenses | - | - | 0.13M | - | - |
| Gross profit | -1.36M | -1.01M | -0.54M | - | - |
| Reconciled depreciation | 1.36M | 1.01M | 0.51M | 0.36M | 0.04M |
| Ebit | -84.11M | -80.56M | -60.39M | -33.02M | -16.18M |
| Ebitda | -82.76M | -79.55M | -59.85M | -32.66M | -16.15M |
| Depreciation and amortization | 1.36M | 1.01M | 0.54M | 0.36M | 0.04M |
| Non operating income net other | - | - | - | 1.49M | - |
| Operating income | -84.11M | -89.20M | -67.24M | -32.66M | -16.18M |
| Other operating expenses | 84.11M | 89.20M | 67.24M | 32.66M | 16.18M |
| Interest expense | - | - | - | -1.49M | 0.06M |
| Interest income | 6.48M | 9.20M | 7.04M | - | - |
| Net interest income | 6.48M | 9.20M | 7.04M | - | - |
| Income tax expense | - | - | 0.00M | -1.49M | 0.06M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 82.76M | 88.19M | 66.70M | 32.66M | 16.18M |
| Cost of revenue | 1.36M | 1.01M | 0.54M | - | - |
| Total other income expense net | 6.21M | 8.64M | 6.85M | 1.49M | -0.06M |
| Net income from continuing ops | -77.91M | -80.56M | -50.06M | -31.17M | -16.24M |
| Net income applicable to common shares | - | - | - | -31.17M | -16.24M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 129.72M | 196.59M | 138.26M | 181.23M | 106.59M |
| Other current assets | 1.86M | 2.15M | 2.23M | 4.34M | 0.81M |
| Total liab | 17.20M | 19.80M | 17.07M | 10.75M | 130.40M |
| Total stockholder equity | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M |
| Other current liab | 12.21M | 15.40M | 7.38M | 4.82M | 1.22M |
| Common stock | 0.03M | 0.03M | 0.02M | 0.02M | 0.00M |
| Capital stock | 0.03M | 0.03M | 0.02M | 0.02M | 0.00M |
| Retained earnings | -274.88M | -196.98M | -116.42M | -56.03M | -24.86M |
| Other assets | - | - | 0.00M | 0.39M | 0.39M |
| Cash | 41.50M | 39.82M | 36.02M | 29.52M | 99.60M |
| Total current liabilities | 15.66M | 17.21M | 13.30M | 6.52M | 2.91M |
| Current deferred revenue | - | - | - | 0.07M | 0.07M |
| Net debt | -38.79M | -36.17M | -31.37M | -24.56M | -93.97M |
| Short term debt | 1.17M | 1.06M | 0.88M | 0.73M | 0.66M |
| Short long term debt total | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M |
| Other stockholder equity | 387.25M | 373.28M | 237.68M | 45.35M | 1.05M |
| Property plant equipment | - | - | - | 2.09M | 5.79M |
| Total current assets | 120.44M | 181.63M | 129.69M | 127.75M | 100.41M |
| Long term investments | 0.00M | 5.09M | 0.00M | 41.88M | - |
| Net tangible assets | - | - | - | 170.47M | -23.81M |
| Short term investments | 77.08M | 139.66M | 91.44M | 98.23M | - |
| Accounts payable | 2.28M | 0.76M | 5.05M | 0.90M | 0.96M |
| Accumulated other comprehensive income | 0.11M | 0.45M | -0.08M | -0.10M | - |
| Common stock total equity | - | - | - | 0.02M | - |
| Retained earnings total equity | - | - | - | -56.03M | - |
| Non currrent assets other | 1.86M | 1.84M | 0.25M | 4.73M | 0.39M |
| Non current assets total | 9.27M | 14.96M | 8.57M | 53.48M | 6.18M |
| Capital lease obligations | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 67.77M | -51.77M | -64.89M | -139.51M | -0.24M |
| Change to liabilities | - | - | - | -0.24M | 0.80M |
| Total cashflows from investing activities | 66.10M | -51.77M | 50.72M | -141.68M | -0.24M |
| Total cash from financing activities | -0.75M | 121.03M | -1.55M | 101.71M | 112.22M |
| Change to operating activities | - | - | - | - | -0.47M |
| Net income | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
| Change in cash | 1.69M | 3.59M | 6.52M | -70.08M | 98.00M |
| Begin period cash flow | 40.02M | 36.43M | 29.91M | 99.99M | 1.99M |
| End period cash flow | 41.70M | 40.02M | 36.43M | 29.91M | 99.99M |
| Total cash from operating activities | -63.66M | -65.67M | -42.64M | -30.12M | -13.98M |
| Issuance of capital stock | 0.00M | 70.00M | 0.00M | 104.46M | 112.22M |
| Depreciation | 0.92M | 1.01M | 0.54M | 0.36M | 0.04M |
| Sale purchase of stock | - | - | - | 101.71M | - |
| Other cashflows from financing activities | -0.75M | 51.03M | -1.30M | -2.75M | -0.24M |
| Change to netincome | - | - | - | 2.19M | 1.90M |
| Capital expenditures | 1.67M | 2.77M | 1.29M | 2.17M | 0.24M |
| Cash flows other operating | - | - | - | -0.56M | - |
| Cash and cash equivalents changes | - | - | - | -70.08M | - |
| Change in working capital | -2.43M | 2.44M | 8.14M | -1.53M | 0.33M |
| Stock based compensation | 14.72M | 14.29M | 11.62M | 2.19M | 0.50M |
| Other non cash items | 1.03M | -2.85M | 1.06M | 0.03M | 1.14M |
| Free cash flow | -65.33M | -68.44M | -43.93M | -32.28M | -14.22M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics, Inc. Common Stock |
0.02 1.36% |
1.48 | - | - | - | 0.97 | -0.43 |
| NVO Novo Nordisk A/S |
-1.21 2.90% |
40.40 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-6.15 1.14% |
531.64 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
4.70 0.49% |
957.10 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter Blume-Jensen M.D., Ph.D. | Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer | 1962 |
| Ms. Kristina Masson Ph.D. | Co-Founder, Exec. VP of Bus. Operations, Treasurer, Sec. & Director | 1980 |
| Dr. Eric J. Devroe Ph.D. | Chief Operating Officer | 1978 |
| Mr. Erick Gamelin M.D., Ph.D. | Chief Medical Officer | 1957 |
| Mr. Rasmus Holm-Jorgensen | Chief Financial Officer | 1971 |
| Ms. Katharine Peterson CPA | VP of Fin. & Accounting | NA |
| Mr. Bruce Close | VP of Quality & Compliance | NA |
| Ms. Mary-Alice Miller J.D. | Gen. Counsel | 1974 |
| Ms. Crystal Mercado | Global Head of HR | NA |
| Dr. Jesper V. Olsen Ph.D. | Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.